![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High Rates of SVR in Patients With HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/r and Sofosbuvir With or Without Ribavirin
|
|
|
Reported by Jules Levin
AASLD Nov 13-17 San Francisco
Stephen Shafran1, David Shaw2, Eric Cohen3, Kosh Agarwal4, Graham R Foster5, Manal Abunimeh3, Bo Fu3, Daniel E Cohen3, Edward Gane6
1University of Alberta Hospital, Edmonton, Alberta, Canada; 2Royal Adelaide Hospital, Adelaide, South Australia, Australia; 3AbbVie Inc., North Chicago, Illinois, United States; 4Institute of Liver Studies, Kings College Hospital, London, United Kingdom; 5Queen Mary University of London, Barts Health, London, United Kingdom; 6Liver Unit, Auckland City Hospital, Auckland, New Zealand
![AASLD1.gif](../images/112015/112015-3/AASLD1.gif)
![AASLD2.gif](../images/112015/112015-3/AASLD2.gif)
![AASLD3.gif](../images/112015/112015-3/AASLD3.gif)
![AASLD4.gif](../images/112015/112015-3/AASLD4.gif)
![AASLD5.gif](../images/112015/112015-3/AASLD5.gif)
![AASLD6.gif](../images/112015/112015-3/AASLD6.gif)
![AASLD7.gif](../images/112015/112015-3/AASLD7.gif)
![AASLD8.gif](../images/112015/112015-3/AASLD8.gif)
![AASLD9.gif](../images/112015/112015-3/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|